<DOC>
	<DOCNO>NCT02150993</DOCNO>
	<brief_summary>FIT-2 multi-country , phase IIb , randomize , non-comparative study , carry West Africa ( Côte d'Ivoire , Burkina Faso , Senegal , Togo , Guinea ) . ARV-naïve HIV-2 infect adult patient recruit follow 96 week . The objective evaluate efficacy safety 3 first-line treatment HIV-2 infect adult patient , West Africa . A treatment consider effective 55 % patient arm attain `` global success '' 96 week .</brief_summary>
	<brief_title>First-Line Treatment HIV-2</brief_title>
	<detailed_description>Main objective To determine treatment-naïve HIV-2 infected patient , CD4 count 200 cells/mm3 , follow three regimen first line treatment , Tenofovir ( TDF ) , Emtricitabine lamivudine ( FTC 3TC ) plus Zidovudine ( ZDV ) ; TDF-FTC ( 3TC ) plus Lopinavir/ritonavir ( LPV / r ) ; TDF-FTC ( 3TC ) plus raltegravir ( RAL ) , result `` global success '' rate &gt; 55 % week 96 . Number participant : 210 Main outcome : The proportion patient `` global success '' W96 , define survival plasma HIV-2 RNA viral load ≤50 copies/ml non-occurrence AIDS classify event ( exclude tuberculosis ) delta CD4 depend initial CD4 count ( CD4 delta &gt; +100cells/mm3 initial CD4s 201 500 cells/mm3 delta &gt; 50 cells/mm3 initial CD4s &gt; +500 cells/mm3 ) Inclusion criterion : - Infection HIV-2 ; - Age &gt; = 18 year ; - Naïve antiretroviral therapy ( include antiretroviral treatment context PMTCT ) - CD4 &gt; 200 cells/mm3 - Resident city study hold city suburb facilitate participation - Signed informed consent</detailed_description>
	<mesh_term>Ritonavir</mesh_term>
	<mesh_term>Lopinavir</mesh_term>
	<mesh_term>Tenofovir</mesh_term>
	<mesh_term>Lamivudine</mesh_term>
	<mesh_term>Zidovudine</mesh_term>
	<mesh_term>Emtricitabine</mesh_term>
	<mesh_term>Raltegravir Potassium</mesh_term>
	<mesh_term>Lamivudine , zidovudine drug combination</mesh_term>
	<criteria>Infection HIV2 ; Age &gt; 18 year ; Naïve antiretroviral therapy ( include antiretroviral treatment context PMTCT ) CD4 &gt; 200 cells/mm3 Resident city study hold city suburb facilitate participation Signed informed consent document Current participation clinical trial Presence opportunistic nonstabilized infection , serious progressive disease , clinical sign consistent severe disease whose diagnosis yet confirm , fever , weight loss , diarrhea cough yet explain ( nonexhaustive list ) . All pathology lead daily life prefer one three therapeutic regimen medical reason change dosage specify test . This include ( limited ) : Hemoglobin ≤ 8 g / dL Neutrophil count &lt; 500 cells/mm3 Renal impairment creatinine clearance &lt; 50mL/mn Decompensated heart failure Hepatic failure Severe ( TP &lt; 50 % cytolysis severe ( ALAT &gt; 3x ULN ) Active TB treatment rifampicin Taking drug interact drug clinical trial ( specify SPC ) Pregnancy , breastfeed plan become pregnant study followup</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Africa</keyword>
	<keyword>Antiretroviral Treatment</keyword>
	<keyword>HIV-2</keyword>
	<keyword>first line ART</keyword>
	<keyword>Adults</keyword>
</DOC>